Literature DB >> 29026920

Immunotherapy as an Option for Cancer Treatment.

Tillmann Rusch1, Jagadeesh Bayry2, Jens Werner1,3, Ivan Shevchenko4, Alexandr V Bazhin5,6.   

Abstract

The progress in melanoma immunotherapy highlights the importance of immunotherapy for cancer treatment. Although the concept of immunotherapy emerged in the beginning of the twentieth century, the end of the century signaled the start of modern immunotherapy, which has recently allowed a staggering progress in the field of cancer immunotherapy. Currently, there is a wide variety of immunotherapeutic approaches and critical improvements are continually being made. Among different immunotherapeutic strategies, therapies based on the blockade of immune checkpoint molecules have shown unparalleled efficacy in late-stage cancer patients. Pre-clinical research using ex vivo and in vivo approaches demonstrates the promise of numerous novel strategies for the immunotherapy of cancer.

Entities:  

Keywords:  Adjuvants; Adoptive cell transfer; Cancer vaccine; Checkpoint inhibitors; Cytokines; Immune editing; Immunotherapy; Monoclonal antibody

Mesh:

Substances:

Year:  2017        PMID: 29026920     DOI: 10.1007/s00005-017-0491-5

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  6 in total

1.  Immunotherapy in anaplastic thyroid cancer.

Authors:  Maoguang Ma; Bo Lin; Mingdian Wang; Xiaoli Liang; Lei Su; Okenwa Okose; Weiming Lv; Jie Li
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

2.  Soluble Programmed Death-Ligand 1 (sPD-L1) is Elevated in Aggressive Prostate Cancer Disease Among African Men.

Authors:  Paul Katongole; Obondo J Sande; Steven J Reynolds; Moses Joloba; Henry Kajumbula; Samuel Kalungi; Kenneth Ssebambulidde; Cynthia Nakimuli; Maxine Atuheirwe; Jackson Orem; Nixon Niyonzima
Journal:  Oncol Ther       Date:  2022-02-07

3.  Reprogramming the murine colon cancer microenvironment using lentivectors encoding shRNA against IL-10 as a component of a potent DC-based chemoimmunotherapy.

Authors:  Joanna Rossowska; Natalia Anger; Agnieszka Szczygieł; Jagoda Mierzejewska; Elżbieta Pajtasz-Piasecka
Journal:  J Exp Clin Cancer Res       Date:  2018-06-28

4.  CTLA-4 Expression Inversely Correlates with Kidney Function and Serum Immunoglobulin Concentration in Patients with Primary Glomerulonephritides.

Authors:  Ewelina Grywalska; Iwona Smarz-Widelska; Sebastian Mertowski; Krzysztof Gosik; Michał Mielnik; Martyna Podgajna; Monika Abramiuk; Bartłomiej Drop; Jacek Roliński; Wojciech Załuska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2019-06-08       Impact factor: 4.291

5.  Combination checkpoint inhibitor therapy induces multiple immune major related adverse events in the treatment of vaginal melanoma: A cautionary case report.

Authors:  T Graham Norwood; Michelle J Wang; Warner K Huh
Journal:  Gynecol Oncol Rep       Date:  2019-10-31

Review 6.  Colorectal Cancer Immunotherapy: Options and Strategies.

Authors:  Nor Adzimah Johdi; Nur Fazilah Sukor
Journal:  Front Immunol       Date:  2020-09-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.